Common shares, no par value
- Symbol
- MDCX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Annual Report · 10-K
MDCXNASDAQEQUITYCurrent
We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").
MEDICUS PHARMA LTD. · 10-K · Filed 2026-03-25